Kymera Therapeutics Claimed Company

Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD. Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development. read more

EMPLOYEE PARTICIPANTS: 12

TOTAL RATINGS: 194

CEO: Nello Mainolfi, PhD

HR or Marketing? Claim Your Free Employer Account

Nello Mainolfi, PhD Kymera Therapeutics CEO Rating

Kymera Therapeutics' CEO, Nello Mainolfi, PhD, has 12 employee ratings and a score of 65/100, placing them in the Bottom 35% of similar size companies on Comparably with 51-200 Employees and Bottom 30% of other companies in Boston.

Last updated months ago.

Where This Score Ranks Kymera Therapeutics' CEO Rating

BOTTOM
35%
In the Bottom 35% of 2034 Similar Sized Companies on Comparably
BOTTOM
30%
In the Bottom 30% of 270 Nearby Companies in Boston
?
Not enough ratings to compare against competitors.

May

Jul

Aug

Sep

Feb

C-65 / 100

May

Kymera Therapeutics CEO Nello Mainolfi, PhD Bio

Co-Founder, President and Chief Executive Officer

Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. Under his leadership, Kymera has built a pipeline of multiple clinical stage, first-in-class degrader medicines; developed a best-in-class drug discovery platform; raised more than $1 billion of capital and formed strategic collaborations with major biopharmaceutical companies. Nello began his career at Novartis, leading cross-functional teams that identified several novel investigational medicines. Before founding Kymera, Nello was an Entrepreneur in Residence at Atlas Venture and previously led discovery research at Raze Therapeutics, a cancer metabolism startup. Nello studied at Imperial College, University of London and The Scripps Research Institute in California and has authored more than 80 publications and patents. He is passionate about helping teams achieve what has not been done before and scaling Kymera into a leading global biopharma company.

Who Ranks Kymera Therapeutics' CEO Rating the Highest?

Not Enough Ratings To Show Who Ranks CEO Rating the Highest

Anonymously rate my experience at Kymera Therapeutics

Who Ranks Kymera Therapeutics' CEO Rating the Lowest?

Not Enough Ratings To Show Who Ranks CEO Rating the Lowest

Anonymously rate my experience at Kymera Therapeutics